Analysts forecast that Wave Life Sciences Ltd (NASDAQ:WVE) will report earnings of ($1.24) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Wave Life Sciences’ earnings, with estimates ranging from ($1.34) to ($1.13). Wave Life Sciences reported earnings of ($1.09) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 13.8%. The company is expected to announce its next earnings results on Monday, March 11th.

According to Zacks, analysts expect that Wave Life Sciences will report full year earnings of ($5.00) per share for the current financial year, with EPS estimates ranging from ($5.12) to ($4.87). For the next fiscal year, analysts expect that the business will post earnings of ($2.97) per share, with EPS estimates ranging from ($5.02) to ($1.06). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVE) last announced its earnings results on Friday, November 9th. The company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.02). The company had revenue of $4.49 million during the quarter, compared to analysts’ expectations of $5.36 million. Wave Life Sciences had a negative return on equity of 112.13% and a negative net margin of 1,114.49%.

A number of equities analysts recently issued reports on WVE shares. HC Wainwright set a $49.00 price objective on Wave Life Sciences and gave the company a “buy” rating in a report on Monday, December 10th. Mizuho set a $65.00 price objective on Wave Life Sciences and gave the company a “buy” rating in a report on Thursday, December 6th. BidaskClub upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. Finally, Leerink Swann started coverage on Wave Life Sciences in a report on Tuesday, November 27th. They set an “outperform” rating and a $61.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $58.20.

Shares of Wave Life Sciences stock opened at $41.54 on Monday. The company has a market capitalization of $1.24 billion, a PE ratio of -10.79 and a beta of 1.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.85 and a quick ratio of 1.85. Wave Life Sciences has a one year low of $32.25 and a one year high of $56.00.

In other Wave Life Sciences news, Director Gregory L. Verdine sold 15,000 shares of Wave Life Sciences stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $38.86, for a total transaction of $582,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 44.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Voya Investment Management LLC raised its position in shares of Wave Life Sciences by 37.8% in the 2nd quarter. Voya Investment Management LLC now owns 6,873 shares of the company’s stock worth $263,000 after acquiring an additional 1,884 shares in the last quarter. Vident Investment Advisory LLC raised its position in shares of Wave Life Sciences by 27.0% in the 2nd quarter. Vident Investment Advisory LLC now owns 12,914 shares of the company’s stock worth $494,000 after acquiring an additional 2,744 shares in the last quarter. Strs Ohio bought a new position in shares of Wave Life Sciences in the 3rd quarter worth $140,000. Wells Fargo & Company MN raised its position in shares of Wave Life Sciences by 0.8% in the 3rd quarter. Wells Fargo & Company MN now owns 363,536 shares of the company’s stock worth $18,178,000 after acquiring an additional 2,903 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Wave Life Sciences by 27.1% in the 3rd quarter. AQR Capital Management LLC now owns 13,828 shares of the company’s stock worth $691,000 after acquiring an additional 2,946 shares in the last quarter. 80.78% of the stock is owned by institutional investors and hedge funds.

About Wave Life Sciences

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Article: Earnings Per Share (EPS) Explained

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.